DR-513 PIP-PREDICT: External validation of biomarkers of immunotherapy response in metastatic melanoma
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-513 PIP-PREDICT: External validation of biomarkers of immunotherapy response in metastatic melanoma
This project aims to validate predictive biomarker models developed in a clinical trial (NCT06536257) by analysing independent patient data obtained …
DR-540 Integrating genomic and transcriptomic profiles to dissect AR reprogramming and lineage plasticity in metastatic castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) is incurable and highly variable between patients and metastatic sites. We will combine whole-genome sequencing …
DR-537 Variation in the 5S ribosomal RNA gene array and its relationship to TP53 status across metastatic cancers
Every cell builds ribosomes, the machines that make proteins. One small ribosomal component, 5S RNA, is encoded by many near-identical …
DR-525 Prostate RNA sequencing atlas
Prostate cancer progresses from normal tissue to a primary cancer, which then subsequently metastasizes and develops resistance to therapies, most …
DR-529 Validation of a genomic pattern as a predictive biomarker for lack of response to platinum-based chemotherapy
Upfront identification of non-responders to platinum-based chemotherapy will prevent ineffective treatment and drug related toxicity, while facilitating the use of …
DR-519 Deciphering the molecular landscape of sarcomas
Sarcomas are rare cancers that are difficult to diagnose and treat due to highly variable genetic profiles. This project uses …
DR-532 Investigating the relationship between extrachromosomal DNA and cancer outcomes
This project studies extrachromosomal DNA (ecDNA), circular DNA fragments that can carry extra copies of cancer-driving genes. We will analyze …
DR-491 Learning the cellular origins of rare cancer using single-cell chromatin landscape
Deciphering the cell of orgin (COO) of different cancers is critial for understanding tumor development and improving diagnostic and therapeutic …
DR-530 Uncovering the effects of genetic background on tumorigenesis through studying mutagenesis and selection
Cancer develops when DNA accumulates mutations over time, with inherited genetic factors influencing whether, when, and how aggressively it progresses. …
DR-539 Validation of RNA-seq derived mutational profiles using paired somatic and germline DNA references in multi-omics tumor profiling
This project evaluates the accuracy of computationally inferring genetic mutations directly from RNA-sequencing data. While RNA-seq is primarily used for …
DR-538 Single-cell analysis reveals possible biomarkers of dormant and awakened prostate cancer cells in bone: exploring clinical applications
When cancer spreads to bone, there is no effective treatment. Cancer cells can survive unnoticed for a long time in …
DR-535 An integrative framework to infer candidate synthetic lethal genetic interactions in Dutch cancer genomes
The objective of this study is to infer candidate genetic interactions (combinations of two mutated genes with advantageous or synthetic …
Unieke dataset Hartwig heeft onze visie op uitgezaaide kanker verrijkt.